First Time Loading...

Silence Therapeutics PLC
NASDAQ:SLN

Watchlist Manager
Silence Therapeutics PLC Logo
Silence Therapeutics PLC
NASDAQ:SLN
Watchlist
Price: 21.3 USD -0.56% Market Closed
Updated: May 3, 2024

Silence Therapeutics PLC
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Silence Therapeutics PLC
Net Income (Common) Peer Comparison

Comparables:
CNTA
AUTL
BCYC
IMCR
GNS

Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Silence Therapeutics PLC
NASDAQ:SLN
Net Income (Common)
-£19.6m
CAGR 3-Years
-32%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Net Income (Common)
-$151.1m
CAGR 3-Years
-142%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Net Income (Common)
-$208.4m
CAGR 3-Years
-14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Net Income (Common)
-$180.7m
CAGR 3-Years
-52%
CAGR 5-Years
-53%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Net Income (Common)
-£55.3m
CAGR 3-Years
9%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Net Income (Common)
£33.4m
CAGR 3-Years
-8%
CAGR 5-Years
N/A
CAGR 10-Years
3%

See Also

What is Silence Therapeutics PLC's Net Income (Common)?
Net Income (Common)
-19.6m GBP

Based on the financial report for Dec 31, 2019, Silence Therapeutics PLC's Net Income (Common) amounts to -19.6m GBP.

What is Silence Therapeutics PLC's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
-32%

Over the last year, the Net Income (Common) growth was -6%. The average annual Net Income (Common) growth rates for Silence Therapeutics PLC have been -32% over the past three years .